The latest information about BioMark Diagnostics to keep you up to date.
BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY
BIOMARK PROVIDES SECOND QUARTER OPERATIONAL UPDATE AND ANNOUNCES EXTENSION TO WARRANT EXERCISE TERM Vancouver, British
BIOMARK STRENGTHENS AND EXPANDS ITS STRATEGIC ADVISORY TEAM IN PURSUIT OF COMMERCIALIZATION INITIATIVES Dr. W.
BIOMARK ANNOUNCES FINANCIAL CONTRIBUTION FROM THE CITY OF QUEBEC TO SUPPORT COMMERCIALIZATION INITIATIVES OF ITS
BIOMARK TO UNVEIL RESULTS OF ITS EARLY BREAST CANCER STUDY AT THE UPCOMING SAN ANTONIO
Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved
Vancouver, British Columbia – (August 30th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
JAPAN PATENT OFFICE (JPO) ISSUED BIOMARK PATENT WITH CLAIMS COVERING ITS LUNG CANCER URINE BASED
BIOMARK Unveils SIGNIFICANT Scientific Advancements from its Leading liquid bioPSY TECHNOLOGY at ASCO 2023 Annual
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2
Rashid A. Bux (CEO)
[email protected]